Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT05140200
PHASE1

Study of GSK3511294 in Healthy Chinese Participants

Sponsor: GlaxoSmithKline

View on ClinicalTrials.gov

Summary

This single dose pharmacokinetic (PK) study aims to investigate the PK, safety, tolerability and immunogenicity of two dose levels of GSK3511294 administered subcutaneously in Chinese healthy participants

Official title: An Open-label, Single Dose Study to Investigate the Pharmacokinetics, Safety, Tolerability and Immunogenicity of Two Dose Levels of GSK3511294 Administered Subcutaneously in Chinese Healthy Participants

Key Details

Gender

All

Age Range

18 Years - 45 Years

Study Type

INTERVENTIONAL

Enrollment

20

Start Date

2021-12-10

Completion Date

2022-12-23

Last Updated

2026-05-26

Healthy Volunteers

Yes

Conditions

Interventions

BIOLOGICAL

Depemokimab

Depemokimab was administered.

Locations (1)

GSK Investigational Site

Hangzhou, China